Pharma Report on Hepatitis C – Pipeline Review, H2 2020


Hepatitis C – Pipeline Review, H2 2020


Hepatitis C – Pipeline Review, H2 2020, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Hepatitis C – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 9, 15, 2, 32, 24 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 13 and 18 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
AB Pharma Ltd
AbbVie Inc
Akshaya Bio Inc
Alla Chem LLC
Ascletis Pharma Inc
Atea Pharmaceuticals Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beta Pharma Inc
Biotest Pharmaceuticals Corp
Biotron Ltd
Bolder Biotechnology Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cocrystal Pharma Inc
Combioxin SA
Cytocom Inc
Dongguan HEC TaiGen Biopharmaceuticals Co Ltd
Ena Therapeutics Pty Ltd
Ennaid Therapeutics LLC
F. Hoffmann-La Roche Ltd
FortuneRock (China) Ltd
Galactica Biotech Ltd
GeneCure LLC
Genoscience Pharma
Gilead Sciences Inc
Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
GlaxoSmithKline Plc
HEC Pharm Co Ltd
Hepion Pharmaceuticals Inc
ImmunoBiology Ltd
Immunotope Inc
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
iQur Ltd
J2H Biotech
Medivir AB
Merck & Co Inc
MetalloPharm LLC
Microbio Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanogen Biopharmaceutical Co
Novalex Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orgenesis Inc
Palisades Therapeutics
PharmaEssentia Corp
Presidio Pharmaceuticals Inc
Profectus BioSciences Inc
Regulus Therapeutics Inc
Riboscience LLC
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Shanghai Newsummit Biopharma Co Ltd
Shanghai Tangrun Pharmaceuticals Co Ltd
Sino Biopharmaceutical Ltd
Sudershan Biotech Ltd
TaiGen Biotechnology Co Ltd
Tetranov International Inc
TGV Laboratories Inc
Therapure Biopharma Inc
THEVAX Genetics Vaccine USA Inc
Toray Industries Inc
Trek Therapeutics PBC
UBI Pharma Inc
Vanworld Pharmaceutical (Rugao) Company Ltd
Vertex Pharmaceuticals Inc
Zylacta Corp

For queries regarding this report:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.